Omeros Corporation and Lonza have entered a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721. Omeros is preparing to submit a biologics license application (BLA) and a marketing authorization application (MAA) to the U.S. FDA and to the European Medicines Agency (EMA), respectively, for narsoplimab for the treatment of hematopoietic s...